INHIBRX BIOSCIENCES, INC.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | — | — | $273.9M |
| FY2023 | $264.4M | $307.9M | $277.9M |
| FY2024 | $47.2M | $180.8M | $152.6M |
| FY2025 | $138.5M | $146.5M | $124.2M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | — | — | $273.9M |
| FY2023 | $264.4M | $307.9M | $277.9M |
| FY2024 | $47.2M | $180.8M | $152.6M |
| FY2025 | $138.5M | $146.5M | $124.2M |